Analyst Price Target is $9.00
▲ +3,972.40% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 3,972.40% upside from the last price of $0.22.
Current Consensus is
The current consensus among 4 contributing investment analysts is to reduce stock in Galera Therapeutics. This Reduce consensus rating has held steady for over two years.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.